sacubitril
Ligand Summary
inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite and leads to increased levels of peptides that are degraded by neprilysin such as natriuretic peptides. It has been approved in combination with valsartan (under the name ENTRESTO) for the treatment of heart failure.
UNII: 17ERJ0MKGI
PubChem: 9811834
ChEMBL: CHEMBL3137301
DrugCentral: 5012
LyCHI: 1DFW7NBLV8Z2
Target Activities
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | INHIBITOR | |||||